eNauka - pregled
Pregled prema Projekat Roche HoldingGenentech
Prikaz rezultata 1 do 3 od 3
| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
|---|---|---|---|---|
| 2020 | Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC | Herbst, Roy S; ...; Andric, Zoran G | Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
| 2020 | Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). | Rodriguez-Abreu, Delvys; ...; Secen, Nevena M; ...; (broj, koautora 20) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC | Jassem, Jacek; ...; Andric, Zoran G | Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |